ALTERITY THERAPEUTICS-ADR (ATHE) Stock News
NASDAQ:ATHE - Nasdaq - US02155X2053 - ADR - Currency: USD
ATHE Latest News and Analysis
Wondering what's happening in today's after-hours session?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
What's Going On With Alterity Therapeutics Shares Thursday?
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical...
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201...
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a...
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – ...
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a...
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –...
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported...
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a...
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a...
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and...
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - ...
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and...
Alterity Therapeutics to Present at MST Financial Webinar
Alterity Therapeutics to Present at MST Financial Webinar
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological...